medtech
How Swissmedic's 2026 targeted action turns PMS plans, data and safety reports into a defined review service.
How do these four analyses build a market view?
Each window links an official source to the entities involved, the attributes that change the decision, the evidence required and the acquisition channels to test. The sector page moves from regulatory signal to opportunity portfolio without confusing developed potential with confidential results.
Health insurance 2024: how did remuneration caps and outreach rules change acquisition?
How the Swiss rules 2024 on remuneration and unsolicited calling had reclassified the acquisition channels in health insurance.
ISA 2024: how did supervision reform change insurance intermediation?
How ISA 2024 had expanded surveillance of intermediaries and shifted trust toward status, organization, and evidence.
ICA 2022: how did the revision change the explanation of insurance contracts?
How the revision of ICA which came into force in 2022 had shifted the value towards rights, prescription and a lasting explanation.
Does your market present a comparable window?
The eligibility report dates and quantifies it, then tests whether it deserves action.
What you will be able to decide
The topic is broken down into entities, attributes, evidence, channels, costs and decision points. Institutions are cited in the text; no external resource interrupts the reading path.
Where is the next buying decision taking shape?
A safety report may be up to date yet still be weak if complaints, incidents, distributor returns and clinical data never lead to a consistent decision. On 23 April 2026, Swissmedic informed Swiss manufacturers and authorised representatives of a new targeted action covering post-market surveillance documentation for class IIa, IIb and III devices. The authority will sample devices and may request plans, analyses and reports. Receipt of the general letter does not mean that an organisation or device has been selected, and it does not imply a deficiency. This insight follows field evidence through to the periodic safety update report. It separates collection, trend analysis, clinical evaluation, vigilance, corrective action and approval . A practical first engagement is a mock review of one device or family, producing a gap register and closure plan. Outreach must remain measured: the offer tests the evidence chain without claiming to predict Swissmedic's sample or using patient safety to create fear. General analysis updated on 7 August 2026. It does not replace a Swissmedic decision, the manufacturer's assessment, or device-specific regulatory or clinical advice.
…
Turn a market change into qualified demand.
When the Medical Devices Regulation was adopted in 2017, manufacturers appeared to have several years to adapt. Its application was later deferred, selected transition periods were extended to 2027 or 2028, and new digital deadlines followed. That shifting timetable can create a false sense of breathing room. A device does not qualify for a transition automatically: its class, certificate, unchanged design and intended purpose, quality system and relationship with a notified body all matter. This reading turns the timetable into portfolio decisions. It explains how to separate devices to continue, remediate, transfer or discontinue; why clinical evidence and regulatory capacity must be assessed together; and what a partner can sell as an initial diagnostic without promising certification. For getfishnet, the opportunity is not fear built around a deadline. It is finding manufacturers whose product decisions, notified-body constraints or Swiss–EU market access needs make a focused review worth buying now. General analysis updated on 7 August 2026. It is not a conformity assessment, individual regulatory advice, or a decision by a notified body or authority.
4 readings · medtech
Does your market present a comparable window?
The eligibility report dates and quantifies it, then tests whether it deserves action.
Test my eligibility